Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Pflanzer

Allergy Desoto, TX Medical Doctor

NPI 1336139377 CMS profile 105830

2801 Bolton Boone Dr, Suite 101, Desoto, TX 75115

Open in the dashboard

General payments

$2,941

133 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Pflanzer of Desoto, TX is reported in the CMS Open Payments database as having received $2,941 across 133 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 51st percentile of Allergy profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $36 2
2023 General $150 7
2022 General $514 25
2021 General $956 44
2020 General $646 34
2019 General $639 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Pflanzer
  • Allergy median
  • Middle half of Allergy
  • National median

In program year 2025, general payments to Joseph Pflanzer were reported at $36. Among 526 Allergy profiles paid that year, the median was $1,143 and the middle half received between $226 and $2,504.

Show as a table
Year Joseph Pflanzer Allergy median Middle half National median
2019 $639 $506 $151–$1,337 $163
2020 $646 $409 $108–$1,162 $114
2021 $956 $549 $125–$1,485 $132
2022 $514 $666 $161–$1,594 $149
2023 $150 $780 $186–$1,916 $160
2024 $0 $1,031 $271–$2,196 $164
2025 $36 $1,143 $226–$2,504 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $776 23 payments
  2. GlaxoSmithKline, LLC. $497 31 payments
  3. Regeneron Healthcare Solutions, Inc. $444 23 payments
  4. Pfizer Inc. $358 15 payments
  5. kaleo, Inc. $188 13 payments
  6. Genentech USA, Inc. $168 2 payments
  7. Genzyme Corporation $93 4 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $67 4 payments
  9. Novartis Pharmaceuticals Corporation $57 3 payments
  10. Sanofi-Aventis U.S. LLC $47 2 payments
  11. Other $247 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,941 133 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Inflammation And Immunology $444 23 payments
  2. EUCRISA $358 15 payments
  3. BREZTRI $307 6 payments
  4. NUCALA Immunology $204 12 payments
  5. AUVI-Q $188 13 payments
  6. FASENRA $168 6 payments
  7. TRELEGY ELLIPTA $146 9 payments
  8. BREZTRI AEROSPHERE $140 2 payments
  9. DUPIXENT Immunology $135 6 payments
  10. NUCALA Respiratory $109 8 payments
  11. Other $661 35 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

226

Median for Allergy/ Immunology: 449

Drug cost

$68,638

Median for Allergy/ Immunology: $169,700

Branded share of claims

25.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 13 $52,690
Epinephrine Generic 55 $9,631
Symbicort Budesonide/Formoterol Fumarate Brand 14 $3,764
Albuterol Sulfate Hfa Albuterol Sulfate Brand 30 $870
Azelastine Hcl Generic 19 $773
Fluticasone Propionate Generic 34 $651
Levocetirizine Dihydrochloride Generic 34 $137
Montelukast Sodium Generic 27 $122

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$70,386

Of which drugs: $208

Medicare patients

147

Average age 71

Services billed

8,815

113 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 27%
Depression 25%
Chronic kidney disease 22%
Osteoporosis 18%
Ischemic heart disease 15%
COPD 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 17 91 $66

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

133 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record